Comparative Pharmacology
Head-to-head clinical analysis: LEVLITE versus LEVORA 0 15 30 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVLITE versus LEVORA 0 15 30 21.
LEVLITE vs LEVORA 0.15/30-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
None Documented
None Documented
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive